69 results about "Parabacteroides" patented technology

The invention discloses parabacteroides faecium capable of relieving senescence and application of the parabacteroides faecium, and belongs to the technical field of microorganisms and the technical field of medicines. Animal experiments prove that Parabacteroides vervae CCFM1428 has the effects of improving the weakness index of a mouse, increasing peroxide dismutase in the liver of the mouse, reducing malonaldehyde, increasing the level of glutathione peroxidase (GSH-px), increasing the level of catalase, reducing an inflammatory factor IL-6, reducing an inflammatory factor TNF-alpha and increasing the level of acetylcholine in the brain of the mouse, and has the effects of improving the weakness index of the mouse, increasing the liver peroxide dismutase of the mouse, reducing malonaldehyde, increasing the level of glutathione peroxidase (GSH-px) and the level of catalase. The gripping force of the mouse is improved. The strain disclosed by the invention has a huge application prospect in preparation of products for relieving senescence.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention discloses a meningioma enteric microbial marker, a product and application of the meningioma enteric microbial marker, and belongs to the field of biological medicine. The invention relates to an enteric microbial marker, which is characterized by being prepared from one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and is characterized in that the enteric microbial marker comprises one or more of the following components: parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius, and the enteric microbial marker comprises one or more of parabacteroides dissoni, prevotella copri, bifidobacterium adolescentis and streptococcus salivarius. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal microbial marker. The invention provides a product for diagnosing meningioma and a computer program product related to meningioma. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of meningioma, and provides a new tool for clinical diagnosis.

Provided are a Parabacteroides strain, a culture, a microbial agent and the use thereof. Specifically provided is a Parabacteroides strain, which can be a strain having a deposit number of GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or a strain having at least 87% average nucleotide identity to the genome of the strain. The strain or a product based on the strain has good effects in terms of preventing or treating tumors or cancers, metabolic diseases, inflammation or autoimmune diseases, infectious diseases and central nervous system diseases.

Provided herein are methods and compositions related to reducing appetite. In some aspects, provided herein are methods of reducing appetite in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The invention discloses pleurotus citrinopileatus polysaccharide as well as a preparation method and application thereof. The pleurotus citrinopileatus polysaccharide is hydrolyzed to obtain a mixture containing glucose, galactose and glucuronic acid. Compared with common edible fungus polysaccharide, the pleurotus citrinopileatus polysaccharide provided by the invention can be used as a carbon source to be specifically utilized by parabacteroides gobi so as to promote metabolism and proliferation of the parabacteroides gobi, and can be applied to prebiotic products of parabacteroides probiotics.

Provides *Parabacterium* strains, cultures, inoculants, and their applications. Specifically, provides a *Parabacterium* strain, which may be a strain with accession number GDMCC No: 62664 or 62665, or a strain with at least 96.74% identity to the strain's 16S rRNA and / or at least 87% average nucleotide identity to the strain's genome; the strain or products based on the strain have good preventive or therapeutic effects on tumors or cancers, metabolic diseases, inflammatory or autoimmune diseases, infectious diseases, and central nervous system diseases.

The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

The application discloses Paracoccus communis C4-4 and C5-3, the preservation number of which is CGMCC NO:31971 and the classification name of which is Paracoccus communis, and the preservation number of which is CGMCC NO:31972 and the classification name of which is Paracoccus communis. Researches show that C4-4 and C5-3 have strong ecological adaptability and good growth promotion ability, and can improve the internal environment of soil in combination with organic materials. A synthetic microbial population constructed by Paracoccus communis comprises C4-4 and C5-3. Tests prove that the synthetic microbial population comprising C4-4 and C5-3 has the advantages of the synthetic microbial population, the microbial population has high alkali production and growth promotion ability, has good ecological adaptability, the pH adaptation range is 4-8, the manganese stress tolerance can reach 5000 μmol / L, can significantly improve the pH of a culture medium, and has obvious alkalization effect. The synthetic microbial population is used as a microbial agent and is compounded with organic materials to prepare a soil conditioner capable of improving acid soil and promoting plant growth. The conditioner is applied to acid and lean soil, can significantly improve the soil pH, improve the content of soil organic matter, nitrogen, phosphorus and potassium, and promote root growth.

The invention relates to the technical field of feed additives, in particular to a sustained-release composition for solving ruminant rumen acidosis as well as a preparation method and application of the sustained-release composition. The composition is prepared from the following components in parts by weight: 30 to 60 parts of complex microbial inoculant capsules, 10 to 30 parts of thiamine, 5 to 15 parts of light calcium carbonate, 5 to 15 parts of magnesium oxide, 8 to 18 parts of sodium bicarbonate, 2 to 5 parts of rare earth elements, 3 to 8 parts of rhizoma coptidis, 5 to 15 parts of rhizoma atractylodis macrocephalae, 4 to 9 parts of poria cocos and 2 to 5 parts of rhizoma corydalis. The complex microbial inoculant capsule at least comprises parabacteroides dieldrii, bacillus subtilis, bacillus licheniformis, enterococcus faecalis and lactobacillus rosenbergii; the rare earth element is a mixture of lanthanum nitrate and cerous nitrate, and the mass ratio of lanthanum nitrate to cerous nitrate is 1: 1. The composition can be used for preventing and treating ruminant rumen acidosis, can be slowly released in the stomach due to the slow release effect, and does not need to be used as a feed additive all the time.

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The invention belongs to the field of biological medicine, and discloses application of parabacteroides dieldrii in preparation of an osteoporosis improving agent. The research of the inventor finds that after the parabacteroides dieldrii is supplemented through intragastric administration, the proportion of Th17 cells can be reduced, secretion of IL-17 and TNF-alpha can be reduced, and the activity of osteoclasts can be inhibited; according to the present invention, with the application of the parabacteroides dieldrii in the preparation of the oral liquid, the osteoporosis can be effectively improved by adding the parabacteroides dieldrii in the stomach, the osteoporosis can be effectively improved, the osteoporosis can be effectively improved, and the great application prospect can be provided, and the effects of the oral liquid such as the intestinal tract, the intestinal tract flora structure, the probiotic (such as the bifidobacterium and the lactobacillus), and the osteoporosis can be effectively improved can be provided.

The invention belongs to the technical field of biological medicines and microorganisms, and particularly relates to a parabacteroides couchneri MRD02 and application thereof, the parabacteroides couchneri is Parabacteroides couchneri MRD02, the preservation number is GDMCC No.64793, and the preservation unit is Guangdong Province Microbial Culture Collection Center. The invention further discloses a preparation method of the parabacteroides couchneri MRD02 and application of the parabacteroides couchneri MRD02. The Parabacteroides goldsteinii MRD02 disclosed by the invention can be used for remarkably inhibiting joint swelling and systemic inflammation of rheumatoid arthritis of mice, and the inhibiting effect of the Parabacteroides goldsteinii MRD02 is remarkably superior to that of other parabacteroides strains; meanwhile, due to the fact that the usage amount of the Parabacteroides goldsteinii MRD02 is small, gastrointestinal reactions of nausea, vomiting or diarrhea are not found in the Parabacteroides goldsteinii MRD02, and anaphylactic reactions are also not found in the Parabacteroides goldsteinii MRD02.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

To provide a composition that increases the occupancy rate of bacterium of the genus Parabacteroides and bacterium of the genus Bifidobacterium in intestinal flora.SOLUTION: A composition for improving intestinal flora is provided, the composition containing any one material selected from trehalulose, isomaltulose, turanose, maltulose, and oligosaccharides containing any one material from these materials as a constituent sugar.SELECTED DRAWING: Figure 1

The invention discloses a preparation method and application of edible fungus polysaccharide capable of effectively promoting proliferation of Parabacteroides in human intestinal tracts, and belongs to the technical field of extraction of edible fungus polysaccharide. The method comprises the following steps: carrying out enzymolysis on Schizophyllumcommuneh sporocarp through a compound enzyme, then carrying out ultrasonic-assisted extraction on enzymatic hydrolysate, carrying out evaporation concentration on the obtained extract, then carrying out Co 60 gamma-irradiation treatment, further carrying out enzymolysis through papain after irradiation is completed, repeatedly freezing and thawing the enzymatic hydrolysate for 2-3 times, then carrying out ethanol precipitation, and drying to obtain the Schizophyllumcommuneh polysaccharide. The Schizophyllumcommuneh polysaccharide prepared by the method is small in molecular weight and high in solubility, can remarkably promote proliferation of paracterobacter, can be used as an ingredient of functional food, and is of great significance to development of functional products for directional regulation and control of intestinal flora.

The invention discloses parabacteroides faecalis PM01 and application thereof in preparation of drugs for treating or preventing diabetes mellitus, and belongs to the technical field of microorganisms. The preservation number of the parabacteroides faecalis PM01 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 22983. The parabacteroides faecalis PM01 has a relatively strong effect of inhibiting alpha-glucosidase in vitro, can remarkably reduce the in-vivo glucose content of a zebra fish hyperglycemia model in vivo, and has the potential of being applied to in-vivo blood glucose level regulation; the invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating diabetes mellitus by utilizing the parabacteroides faecalis PM01.

Provided herein are compositions comprising in vivo succinate-producting microorganisms, e.g., Bacteroides and Prevotella species (preferably Bacteroides thetaiotaomicron (e.g., VPI 5482), Bacteroides vulgatus (e.g., NCTC 11154, Prevotella copri (e.g., DSM 18205)), Parabacteroides (e.g., Parabacteroides distasonis), and Bacilli (e.g. Lactobacillus animalis), and methods of use thereof in treating or reducing risk of developing an intestinal infection, optionally an infection with Campylobacter, Salmonella, E. coli, Shigella, Listeria monocytogenes, Vibrio, Enteropathogenic E. coli, Klebsiella, or Clostridioides difficile, or promoting expansion of colonic tuft cells, in a subject.

The invention discloses a primer composition for detecting bifidobacterium bifidum of which the microbial preservation number is CCTCC (China Center for Type Culture Collection) NO: M2023349, enterococcus avium of which the microbial preservation number is CCTCC NO: M2023350, lactobacillus salivarius of which the microbial preservation number is CCTCC NO: M2023348, lactobacillus fermentum of which the microbial preservation number is CCTCC NO: M2023352, and parabacteroides didysonii of which the microbial preservation number is CCTCC NO: M20222033. The invention further discloses a kit based on the primer composition and application of the kit. The primer composition has good specificity and high accuracy aiming at the five bacteria, and can detect the five bacteria in a complex environment to evaluate the physiological status of a subject.

The present invention discloses Parabacteroides distasonis NSP007 for alleviating insulin resistance and its application, belonging to the field of microbial technology. Parabacteroides distasonis NSP007 of the present invention can inhibit the weight gain and body fat accumulation of IR mice without affecting food intake; improve the glucose tolerance and insulin sensitivity of IR mice, while reducing the serum insulin and insulin resistance index of mice; regulate the lipid metabolism disorder of IR mice and relieve liver tissue damage; improve the intestinal barrier function of IR mice. The Parabacteroides distasonis NSP007 of the present invention is used for preparing a pharmaceutical composition for alleviating IR, and has very broad application prospects.

The invention discloses an application of parabacteroides faecalis PM01 in preparation of drugs for preventing or treating inflammatory diseases, and belongs to the technical field of microorganisms. According to the application of the parabacteroides faecalis PM01 in preparation of the medicine for preventing or treating the inflammatory diseases, the parabacteroides faecalis PM01 can inhibit neutrophil and macrophage from gathering towards the inflammation position of the tail fin of zebra fish in an in-vivo inflammation model; the parabacteroides faecalis PM01 can be used for inhibiting the increase of the content of LPS-induced inflammatory factors IL-1beta, IL-6 and TNF-alpha (Tumor Necrosis Factor-alpha); theoretical reference and guidance basis are provided for developing medicines for preventing or treating inflammatory diseases by utilizing the parabacteroides faecalis PM01.

The present application relates to the technical field of exosome application, and specifically discloses a psoriasis treatment use of Parabacteroides exosomes. The Parabacteroides is selected from any one or more of Parabacteroides distasonis, Parabacteroides gordonii, Parabacteroides johnsonii, Parabacteroides merdae and Parabacteroides goldsteinii. The exosomes of the present application, especially Parabacteroides goldsteinii, have excellent effects in treating psoriasis.

The invention provides application of parabacteroides dieldrii in preparation of a medicine for treating sepsis, and belongs to the technical field of microorganisms. According to the application disclosed by the invention, the sepsis is treated by utilizing the parabiosis dielsii ATCC: 8503, the treatment effect of the parabiosis dielsii ATCC: 8503 is detected, and a result proves that after the parabiosis dielsii ATCC: 8503 is given, the survival rate of mice with sepsis can be obviously increased, the contents of ALT, AST, BUN and Creatinine in serum can be reduced, meanwhile, the wet / dry weight ratio of lung is reduced, and the liver, lung and kidney injury caused by sepsis is effectively relieved.

To find out a useful living body-regulating function in a treated product of Abelmoschus manihot and to provide a functional use thereof.SOLUTION: An intestinal environment-improving agent comprising a processed product of Abutilon striata as an active ingredient, wherein the intestinal environment-improving agent increases bacteria of the genus Lactobacillusmurinus and / or the genus Parabacteroides.SELECTED DRAWING: Figure 5

The application discloses application of Bacteroides dorei and succinic acid in treatment of radiohematopoietic injury aggravated by microplastics. The application explores the influence of polystyrene particles, which are representative of microplastics, on hematopoietic injury induced by ionizing radiation, identifies beneficial intestinal microorganisms and metabolic products playing a key role therein, and verifies the replenishment effect, thereby screening the key intestinal microorganism Bacteroides dorei and the metabolic product succinic acid and its salts having the effect of relieving radiohematopoietic injury aggravated by microplastics. The application provides intervention materials and thought strategies for radiohematopoietic injury aggravated by microplastics, provides a basis and application basis for tumor radiotherapy, and has important practical significance and clinical transformation value.

There is provided bacterial compositions for treatment of bipolar disorder or symptoms thereof and methods of treating bipolar disorders or symptoms there of using the same. The compositions comprise a community of fecal bacteria, wherein the community of fecal bacteria comprise bacteria from the genus Agathobacter, Anaerotignum, Bacteroides, Bifidobacterium, Butyricimonas, Dialister, Dysosmobacter, Eubacterium, Odoribacter and Parabacteroides.

The invention discloses a parabacteroides strain, a culture, a fungicide and application of the parabacteroides strain, the culture and the fungicide. In a first aspect of the present application, a strain of the genus Parabacteroides is provided, which can be a strain having a preservation number GDMCC No: 62664 or 62665, or a strain having at least 96.74% identity to the 16S rRNA of the strain, and / or having at least 87% average nucleotide identity to the genome of the strain. According to the embodiment of the invention, a new strain under parabacteroides is newly found, and the strain or a product based on the strain has good effects of preventing or treating tumors or cancers, metabolic diseases, inflammations or autoimmune diseases, infectious diseases and central nervous system diseases.

Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The invention belongs to the field of biological medicine, and particularly relates to application of a fluorinated quinoline derivative in inhibition of colon cancer pathogenic bacteria. The invention firstly provides a fluorinated quinoline derivative or a pharmaceutical salt thereof; the fluorinated quinoline derivative can inhibit fusobacterium nucleatum, has no inhibition effect on common intestinal bacteria such as bifidobacterium animalis subsp. Lactis, mucophilic protein-ackermania, bacteroides multiforme, clostridium sporogenes, lactobacillus reuteri, parabacteroides dielsii and the like, and has the characteristics of good fusobacterium nucleatum resistance activity and specificity; the fusobacterium nucleatum can be used for treating diseases caused by fusobacterium nucleatum infection.

The invention provides application of parabacteroides dieldrii in preparation of a medicine for treating Parkinson's disease. The parabacteroides dieldrii can play a neuroprotective role through multiple mechanisms of regulating intestinal flora, reducing neuroinflammation, improving a blood-brain barrier function and the like. Animal experiments show that the active parabacteroides dielsii can significantly improve PD mouse dyskinesia, protect dopaminergic neurons, repair intestinal and central barriers, and remodel a metabolite spectrum related to nerve regulation. The intestinal symbiotic bacterium parabacteroides dieldrii provided by the invention has a good effect of treating the Parkinson's disease, and has a wide application prospect in the field of micro-ecological treatment of the Parkinson's disease.